Study Assessing Immunogenicity and Safety of IC43 In Intensive Care Patients
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
Randomized, placebo-controlled, partially blinded phase 2 pilot study. Multicenter study
(approximately 50 centers) in approximately 9 countries. Proposed start date is December
2008. The study duration per patient is estimated to be 90 days. Overall study duration is
estimated to be 12-18 months.